Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

Biotechnology • Healthcare • Boulder, CO, United States • ELVN (NMS)

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

720 647 8519 6200 Lookout Road, Boulder, CO 80301, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MarketBeat • Jan 2
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PR Newswire
PR Newswire • Nov 12
Enliven Therapeutics (ELVN): Evaluating Valuation After a Recent Share Price Rebound and Ongoing Clinical Progress - Yahoo Finance
Yahoo Finance • Dec 9
Enliven Therapeutics (Nasdaq: ELVN) taps Rick Fair as CEO, ex-Bellicum chief - Stock Titan
Stock Titan • Dec 11
First Week of February 2026 Options Trading For Enliven Therapeutics (ELVN) - Nasdaq
Nasdaq • Dec 22

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Enliven Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Enliven Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Enliven Therapeutics, Inc. have?
Enliven Therapeutics, Inc. has approximately 65 employees.
What industry is Enliven Therapeutics, Inc. in?
Enliven Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Enliven Therapeutics, Inc. a publicly traded company?
Yes, Enliven Therapeutics, Inc. is publicly traded under the ticker symbol ELVN on the NMS. The company has a market capitalization of approximately $0.97 billion.
Where is Enliven Therapeutics, Inc. headquartered?
Enliven Therapeutics, Inc. is headquartered in Boulder, CO, United States at 6200 Lookout Road, Boulder, CO 80301, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.